- Home
- DRIO vs PRLD Comparison
DRIO vs PRLD Comparison
Compare DRIO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRIO | PRLD |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 207.5M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DRIO | PRLD |
|---|---|---|
| Price | $8.51 | $3.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $60.00 | $4.67 |
| AVG Volume (30 Days) | 8.3K | ★ 316.0K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ 9.05 | N/A |
| Revenue | $7,394,000.00 | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $16.15 | $100.00 |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | 43.02 | ★ 73.43 |
| 52 Week Low | $0.38 | $0.61 |
| 52 Week High | $17.74 | $4.19 |
Technical Indicators
Market Signals| Indicator | DRIO | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 57.58 |
| Support Level | $0.56 | $1.02 |
| Resistance Level | $12.36 | $4.10 |
| Average True Range (ATR) | 0.66 | 0.31 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 18.14 | 50.68 |
Price Performance
Historical ComparisonAbout DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.